267 related articles for article (PubMed ID: 23558940)
61. Germline mutations in the von Hippel-Lindau gene in Italian patients.
Ciotti P; Garuti A; Gulli R; Ballestrero A; Bellone E; Mandich P
Eur J Med Genet; 2009; 52(5):311-4. PubMed ID: 19464396
[TBL] [Abstract][Full Text] [Related]
62. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
63. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
64. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma.
Brauch H; Weirich G; Hornauer MA; Störkel S; Wöhl T; Brüning T
J Natl Cancer Inst; 1999 May; 91(10):854-61. PubMed ID: 10340905
[TBL] [Abstract][Full Text] [Related]
65. Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma.
Zhou J; Wang J; Li N; Zhang X; Zhou H; Zhang R; Ma H; Zhou X
Pathol Int; 2010 Jun; 60(6):452-8. PubMed ID: 20518900
[TBL] [Abstract][Full Text] [Related]
66. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
67. Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion.
Vortmeyer AO; Huang SC; Pack SD; Koch CA; Lubensky IA; Oldfield EH; Zhuang Z
Oncogene; 2002 Feb; 21(8):1167-70. PubMed ID: 11850836
[TBL] [Abstract][Full Text] [Related]
68. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis.
Lott ST; Chandler DS; Curley SA; Foster CJ; El-Naggar A; Frazier M; Strong LC; Lovell M; Killary AM
Cancer Res; 2002 Apr; 62(7):1952-5. PubMed ID: 11929809
[TBL] [Abstract][Full Text] [Related]
69. [Frequent somatic mutations of the von Hippel-Lindau (VHL) tumor suppressor gene and its meaning in sporadic human renal clear cell carcinoma].
Gong K; Zhang N; Guo HF; Zhang ZW; Xin DQ; Na YQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):169-72. PubMed ID: 15100736
[TBL] [Abstract][Full Text] [Related]
70. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.
Jilg CA; Neumann HP; Gläsker S; Schäfer O; Ardelt PU; Schwardt M; Schultze-Seemann W
Urol Int; 2012; 88(1):71-8. PubMed ID: 22156657
[TBL] [Abstract][Full Text] [Related]
71. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
72. Mutations of the VHL tumour suppressor gene in renal carcinoma.
Gnarra JR; Tory K; Weng Y; Schmidt L; Wei MH; Li H; Latif F; Liu S; Chen F; Duh FM
Nat Genet; 1994 May; 7(1):85-90. PubMed ID: 7915601
[TBL] [Abstract][Full Text] [Related]
73. [Prevention of renal carcinoma: the nutri-genetic approach].
Junien C; Dupret JM; Gallou C; Longuemaux S; Richard S; Saquet C; Krishnamoorty R; Delomenie C; Droz D; Bouvier R; Chauveau D; Joly D; Grunfeld JP; Chretien Y; Mejean A; Beroud C
J Soc Biol; 2000; 194(1):29-38. PubMed ID: 11107547
[TBL] [Abstract][Full Text] [Related]
74. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
[TBL] [Abstract][Full Text] [Related]
75. Retroperitoneal paraganglioma with loss of heterozygosity of the von Hippel-Lindau gene: a case report and review of the literature.
Anno M; Izawa S; Fujioka Y; Matsuzawa K; Saito K; Hikita K; Makishima K; Nosaka K; Takenaka A; Usui T; Yamamoto K
Endocr J; 2022 Sep; 69(9):1137-1147. PubMed ID: 35466127
[TBL] [Abstract][Full Text] [Related]
76. Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.
Guinot A; Lehmann H; Wild PJ; Frew IJ
J Pathol; 2016 Jul; 239(3):365-73. PubMed ID: 27126173
[TBL] [Abstract][Full Text] [Related]
77. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
[TBL] [Abstract][Full Text] [Related]
78. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
[TBL] [Abstract][Full Text] [Related]
79. Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas.
Yang K; Lindblad P; Egevad L; Hemminki K
Cancer Lett; 1999 Jul; 141(1-2):1-8. PubMed ID: 10454237
[TBL] [Abstract][Full Text] [Related]
80. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.
Patard JJ; Rioux-Leclercq N; Masson D; Zerrouki S; Jouan F; Collet N; Dubourg C; Lobel B; Denis M; Fergelot P
Br J Cancer; 2009 Oct; 101(8):1417-24. PubMed ID: 19755989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
